HBMN:SWX
HBM Healthcare Investments AG
CHF 235.00
arrow_upward
+1.29%(+3.00) 1 天
4月30日, GMT+2 17:31:54 · CHF
search
所有股票代码
1 天
5 天
1 个月
6 个月
年初至今
1 年
5 年
最大
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 HBMN 生成关键数据洞见…
开盘价
CHF 231.50
最高价
CHF 235.00
最低价
CHF 228.00
市值
一五.八四亿
平均成交量
六三八〇.〇〇
成交量
二八一三.〇〇
股息
三.一九%
季度股息
CHF 1.88
除息日
2025年7月2日
市盈率
六.五四
52 周最高价
CHF 245.50
52 周最低价
CHF 157.40
每股收益
CHF 35.93
流通股数
六七四.〇〇万
新闻报道
来自全网
资料
HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.
A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities.
Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies" In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch. HBM is based in Zug and managed by HBM Partners. HBM acquired rival Swiss VC International BM Biomedicine in 2005. Wikipedia
HBM Healthcare Investments AG简介